Literature DB >> 31123030

Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in NPM1 mutant acute myeloid leukemia.

Alvaro de Santiago de Benito1, Barbara Jeker1,2, Eva Gfeller3, Naomi Porret3, Yara Banz4, Urban Novak1,2, Ulrike Bacher3, Thomas Pabst5,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31123030      PMCID： PMC6939523          DOI： 10.3324/haematol.2019.216457

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome.

Authors:  N Feller; G J Schuurhuis; M A van der Pol; G Westra; G W D Weijers; A van Stijn; P C Huijgens; G J Ossenkoppele
Journal:  Leukemia       Date:  2003-01       Impact factor: 11.528

2.  Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission.

Authors:  Norbert-Claude Gorin; Myriam Labopin; Josy Reiffers; Noel Milpied; Didier Blaise; Francis Witz; Theo de Witte; Giovanna Meloni; Michel Attal; Teresa Bernal; Vanderson Rocha
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

3.  The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potential.

Authors:  Isabelle von Grünigen; Joëlle Raschle; Ilka Rüsges-Wolter; Behrouz Mansouri Taleghani; Beatrice U Mueller; Thomas Pabst
Journal:  Leuk Res       Date:  2012-06-23       Impact factor: 3.156

4.  Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years.

Authors:  Alexander D Heini; Martin D Berger; Katja Seipel; Behrouz Mansouri Taleghani; Gabriela M Baerlocher; Kurt Leibundgut; Yara Banz; Urban Novak; Thomas Pabst
Journal:  Leuk Res       Date:  2016-12-08       Impact factor: 3.156

5.  Pitfalls in the molecular follow up of NPM1 mutant acute myeloid leukemia.

Authors:  Ulrike Bacher; Naomi Porret; Raphael Joncourt; Javier Sanz; Nijas Aliu; Gertrud Wiedemann; Barbara Jeker; Yara Banz; Thomas Pabst
Journal:  Haematologica       Date:  2018-06-14       Impact factor: 9.941

Review 6.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

7.  Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission.

Authors:  Norbert-Claude Gorin; Myriam Labopin; Thomas Pabst; Peter Remenyi; Depei Wu; Anne Huynh; Liisa Volin; Jean Yves Cahn; Ibrahim Yakoub-Agha; Melanie Mercier; Mohamed Houhou; Mohamad Mohty; Arnon Nagler
Journal:  Am J Hematol       Date:  2017-09-28       Impact factor: 10.047

8.  Iron overload is correlated with impaired autologous stem cell mobilization and survival in acute myeloid leukemia.

Authors:  Laura C Alva; Ulrike Bacher; Katja Seipel; Behrouz Mansouri Taleghani; Beatrice U Mueller; Urban Novak; Thomas Pabst
Journal:  Transfusion       Date:  2018-09-10       Impact factor: 3.157

9.  Assessment of Minimal Residual Disease in Standard-Risk AML.

Authors:  Adam Ivey; Robert K Hills; Michael A Simpson; Jelena V Jovanovic; Amanda Gilkes; Angela Grech; Yashma Patel; Neesa Bhudia; Hassan Farah; Joanne Mason; Kerry Wall; Susanna Akiki; Michael Griffiths; Ellen Solomon; Frank McCaughan; David C Linch; Rosemary E Gale; Paresh Vyas; Sylvie D Freeman; Nigel Russell; Alan K Burnett; David Grimwade
Journal:  N Engl J Med       Date:  2016-01-20       Impact factor: 91.245

Review 10.  Autologous Transplantation for Older Adults with AML.

Authors:  Beatrice U Mueller; Katja Seipel; Ulrike Bacher; Thomas Pabst
Journal:  Cancers (Basel)       Date:  2018-09-19       Impact factor: 6.639
View more
  3 in total

1.  Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML.

Authors:  Ekaterina Gurevich; Michael Hayoz; Yolanda Aebi; Carlo R Largiadèr; Behrouz Mansouri Taleghani; Ulrike Bacher; Thomas Pabst
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

2.  Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation.

Authors:  Evgenii Shumilov; Inna Shakhanova; Johanna Flach; Nicole Schmidt; Susanne Buerki; Myriam Legros; Marie-Noëlle Kronig; Yishai Ofran; Sabine Gerull; Michael Medinger; Behrouz Mansouri Taleghani; Jakob Passweg; Jörg Halter; Ulrike Bacher; Thomas Pabst
Journal:  Bone Marrow Transplant       Date:  2021-11-13       Impact factor: 5.483

Review 3.  The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.

Authors:  Anna Czyz; Arnon Nagler
Journal:  Int J Mol Sci       Date:  2019-10-28       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.